INTRODUCTION
The prevalence of diabetes is overwhelming nowadays, with worldwide more than 345 million people suffering from diabetes (Anonymous, 2012) . Type 2 diabetes comprises 90% of people with diabetes around the world, and is largely the result of excess body weight and physical inactivity (Anonymous, 2012) . Although life-style interventions, such as dietary adjustments and increased exercise, are initially very effective (and with low costs), longterm adherence is in general poor. Therefore, most type 2 diabetic patients will inevitably need treatment with one or more antidiabetic drugs to manage their hyperglycemia. This treatment mainly includes drugs from the class of oral antidiabetics such as metformin, sulfonylureas, and thiazolidinediones (Kalliokoski et al., 2010) . The American Diabetes Association and the European Association for the Study of Diabetes recently published a consensus statement providing a guidance for treatment of hyperglycemia in type diabetic patients (Nathan et al., 2009) . According to this guideline, treatment of type 2 diabetes with metformin or sulfonylureas belongs to the class 1 category of well-validated core therapies as it has been in clinical use for over 50 years now, whereas treatment with thiazolidinediones is less well validated and has been associated with serious cardiovascular side effects (Aquilante, 2010; Nathan et al., 2009) . Notably, type 2 diabetic patients often concomitantly receive therapeutic drugs directed against other coincident features, such as dyslipidemia and hypertension, and it is therefore important to investigate possible drug-drug interactions.
Many oral drugs (including oral antidiabetics and the lipid-lowering statins) are extracted from the portal blood by the liver before they reach their target, which can either be intrahepatic (e.g. statins, metformin) or extrahepatic (e.g. pancreatic cells in case of sulfonylureas, or adipocytes in case of thiazolidinediones). In this study we focus on the organic anion transporting polypeptide 1B1 (OATP1B1; gene SLCO1B1) as one of the main hepatic uptake transporters (Hagenbuch and Meier, 2004) . OATP1B1 can transport a wide This article has not been copyedited and formatted. The final version may differ from this version. variety of drugs, including many statins (e.g. rosuvastatin, pravastatin, pitavastatin) and some oral antidiabetics (repaglinide, troglitazone) (Fahrmayr et al., 2010; König et al., 2006; Niemi et al., 2005; Nozawa et al., 2004) . The clinical importance of OATP1B1 in the pharmacokinetics of drugs has been confirmed by several studies that focused on the effect of commonly occurring single nucleotide polymorphisms in OATP1B1. In particular, the OATP1B1*15 variant (Asn130Asp and Val174Ala), with an average haplotype frequency of 16-24% in Europe and America (Pasanen et al., 2008) , is generally known to have a strongly reduced transport activity and has been associated with markedly increased plasma levels of certain OATP1B1 substrates. This might be advantageous for some drugs that do not have a target in the liver, resulting in an increased pharmacological response. However, for drugs that have a target inside the liver, decreased hepatic uptake by OATP1B1*15 might result in decreased pharmacological response and give rise to unforeseen toxic side effects. Indeed, it has been demonstrated that patients carrying the OATP1B1*15 variant show markedly increased plasma levels, decreased pharmacological response and even increased extrahepatic toxicity for instance after pravastatin, pitavastatin or rosuvastatin treatment (Choi et al., 2008; Chung et al., 2005; Fahrmayr et al., 2010; Igel et al., 2006; Niemi et al., 2004; Niemi et al., 2011) .
Although glyburide, troglitazone and pioglitazone have previously been reported as inhibitors of OATP1B1 (Bednarczyk, 2010; Gui et al., 2009; Hirano et al., 2006; Nozawa et al., 2004) , the effects of a complete set of oral antidiabetic drugs on both OATP1B1 and OATP1B1*15 have not been systematically studied before. In this study we therefore aimed to reveal the possible drug-drug interactions between several oral antidiabetic drugs belonging to the class of sulphonylureas and thiazolidinediones and the lipid-lowering drug rosuvastatin at the level of OATP1B1.We also included studies that explore the influence of the *15 haplotype on this interaction. This article has not been copyedited and formatted. The final version may differ from this version. 
Construction of HEK293 cells stably expressing OATP1B1*1a or OATP1B1*15
Subcloning of human OATP1B1*1a (NM_006446.4 referring to wild-type; hereafter named OATP1B1) or OATP1B1*15 cDNA into the pIRESpuro vector was performed by GeneArt (Invitrogen, Germany). HEK293 (ATTC, Germany; lot# 57954093) cells were seeded in 6-wells plates at a density of 9*10 5 cells/well and grown for 24 hours, followed by co-transfection with pcDNA3.1-Ukcol (0.3 µg/well) and pIRESpuro-OATP1B1 or -OATP1B1*15 (2.7 µg/well) using 6 equivalents of Exgen 500 (Fermentas, MBI). Parental HEK293 cells co-transfected with pcDNA3.1-Ukcol and empty pIRESpuro vector (HEK-MOCK) served as control. After 24 hours, the transfected cell lines were cultured in medium containing puromycin (1 µg/mL), and after 3-4 weeks several colonies were selected and grown into 75 cm 2 tissue culture flasks. Excretion of UKcol into the medium of cells of the different colonies was used to select colonies for further analyses.
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Immunocytochemical staining
HEK-MOCK, HEK-OATP1B1, and HEK-OATP1B1*15 cells were seeded on Thermanox plastic coverslips (NUNC, Rochester) coated with 0.1 mg/mL Poly-D-Lysine (Sigma-Aldrich) in 24-well plates at a density of 4*10 5 cells/well and grown for 48 hours at 37˚C with 5% CO 2 . Cells were fixated with ice-cold methanol for 30 minutes at -20°C, followed by incubation with the mouse monoclonal primary OATP1B1 antibody (1:100; ESL clone, ab15441, AbCam) for 1 hour at RT. After removal of the primary antibody, cells were incubated for 1 hour at RT with the secondary goat anti-mouse antibody (1:100; Alexa 488, Invitrogen). Cells were washed three times with PBS and de-mineralized water, followed by step-wise dehydration with 50% and 100% methanol. Subsequently, the cover glasses were removed from the wells, mounted on slides with 4.8% Mowiol (Polysciences Inc.) mounting medium and used for analyses by fluorescent microscopy (Leica, Rijswijk, The Netherlands).
Membrane isolations
To determine the active transporter protein expression levels in transfected cells, the outer cellular membranes were isolated using a sucrose density gradient centrifugation protocol. After trypsinisation (~5 x 10 7 cells), cell pellets were re-suspended in hypotonic buffer (0.5 mM sodium phosphate, 0.1 mM EDTA, and a cocktail of protease inhibitors containing 2 mM phenylmethylsulfonylfluoride, aprotinin, leupeptin, and pepstatin). After one hour of incubation at 4°C, the homogenized cells were centrifuged at 100,000 x g for 30 minutes at 4°C using a LE-80k Centrifuge with SW28 rotor (Beckman Counter, USA). The pellet was re-suspended in hypotonic buffer followed by the addition of two volumes of isotonic buffer (10 mM Tris-Hepes and 250 mM sucrose (pH 7.4)). The extract was again homogenized using a Potter-Elvehjem homogenizer and centrifuged at 12,000 x g for 10 minutes at 4°C. The supernatant was collected and centrifuged at 100,000 x g for 30 minutes at 4°C. The pellet was re-suspended in isotonic buffer and was layered on top of a 38% sucrose solution and centrifuged at 100,000 x g for 90 minutes at 4 °C. The turbid layer at the interface, containing the plasma membranes, was recovered, diluted with isotonic buffer and centrifuged at 100,000 x g for 40 minutes at 4°C. The plasma membrane fraction was obtained from the resulting pellet, which was re-suspended in 50 µL isotonic buffer. Protein levels were measured using the Bradford method (Biorad, USA).
Protein digestion
Isolated plasma membrane extracts (~50 µg) from individual cell lines were diluted with 2 volumes of 90% methanol. The proteins were subsequently reduced with 0.01 M dithiothreitol at 37°C for 60 minutes and alkylated with 0.04 M iodoacetamide for 20 minutes at room temperature in the dark. Digestion was performed after addition of CaCl 2 (final concentration 1 nM) and 0.5 µg trypsin (Promega) in 17% methanol by diluting the solution with 50 mM NH 4 HCO 3 . After overnight incubation the samples were incubated for another 2 hours with 0.5 µg trypsin. The efficiency of the tryptic digestion was checked using SDS-PAGE followed by silver stain. Finally the protein digests were evaporated by 
LC-MS/MS analysis
The peptide analysis was performed on a UPLC coupled to a Xevo TQ-S mass spectrometer (Waters). The extract (7.5 µL) was injected on a Acquity C18 BEH UPLC column (2.1 x 100 mm, 1.7 µm) and was separated using gradient elution with a stable flow of 600 µL/minute. The gradient started with 95% A (milliQ water with 0.1% formic acid) and 5% B (acetonitrile with 0.1% formic acid) followed by a linear increase to 45% B which was achieved at 5.0 minutes. Subsequently, the gradient was linearly increased within 0.1 minutes to 100% B and maintained for 2 minutes. The system subsequently switched to 5% B, which was achieved at 7.1 minutes, after which the column equilibrated at 95% A for approximately 3 minutes. The column was maintained at 50°C during analysis, and the samples were kept at 10°C. Blank injections were run after each sample and the needle and terminated by washing the cells with 0.4 ml ice-cold HBSS/HEPES + 0.5% BSA and twice with 0.4 ml ice-cold HBSS/HEPES, followed by the addition of 0.2 mL 0.5% Triton X-100, of which 0.15 mL of the cell lysate was transferred to a 5 mL plastic scintillation vial for radioactivity measurement by liquid scintillation counting (Perkin Elmer).
Experiments performed in the laboratory of Janssen Pharmaceutical Companies of
Johnson & Johnson (J&J) were carried out according to the above mentioned protocol, with three minor differences: cells were seeded at a density of 4*10 5 cells/well on collagen coated 24-wells plates (BD biosciences) and grown to confluence for 24 hours, the uptake was terminated by washing the cells with 1.5 ml ice-cold HBSS/HEPES, followed by the addition of 0.2 mL mPER-lysis (Thermo Scientific).
Data analysis
Uptake into mock-transfected cells served as a control in all experiments to correct for uptake that was not related to OATP1B1-mediated transport. The two-sided unpaired Student's t-test was used to assess the statistical significance of differences between two sets of data. Results are presented as the means ± S.D.
Differences were considered to be statistically significant when P < 0.05.
This article has not been copyedited and formatted. The final version may differ from this version. Figure   1A and 1B). No staining was observed in the vector-transfected control cells (HEK-mock; Figure 1C ). The absolute protein expression of OATP1B1 at the cell membrane of HEK-OATP1B1 and HEK-OATP1B1*15 cells was determined using a LC-MS/MS method, based on the method previously described by Kamiie et al. (Kamiie et al., 2008) . Importantly, the protein expression of OATP1B1 and OATP1B1*15 at the outer cell membrane of both cell lines was comparable (9.8 ± 2.3 and 8.5 ± 1.9 pmol OATP1B1/mg membrane protein, respectively; Figure 2 ), justifying direct comparison of these two cell lines without further corrections.
Functional characterization of the HEK-OATP1B1 and HEK-OATP1B1*15 cells
The uptake of the control substrate [ (Kindla et al., 2011; Roth et al., 2011) , however the underlying molecular mechanism and clinical relevance has remained unclear.
This article has not been copyedited and formatted. The final version may differ from this version. Within the class of sulfonylureas it appeared that increased lipophilicity of these anti diabetic drugs was associated with a more potent inhibition of OATP1B1-mediated transport of rosuvastatin ( Figure 6 ).
This article has not been copyedited and formatted. The final version may differ from this version. antidiabetics after the maximum dose in patients. Since the concentration of orally taken drugs is the highest in the portal vein (resulting from intestinal absorption), we estimated the drug concentration in portal venous blood by the method described by Ito et al. (Ito et al., 1998 ). The C max in patients taking glyburide (1.25 mg), glipizide (5 mg), glimepiride (5 mg) or troglitazone (600 mg) has been reported at 0.77, 1.04, 0.73 and 6.4 μ M (Brunton et al., 2011; Spencer and Markham, 1997; Zheng et al., 2009) (Brunton et al., 2011; Spencer and Markham, 1997; Zheng et al., 2009) , the unbound concentration is expected to be only a fraction of the total plasma concentration and are mainly below the IC 50 values observed in this study. Similar conclusions were drawn by Hirano et al (Hirano et al., 2006) , who stated that although OATP1B1-mediated pitavastatin uptake was inhibited by glyburide in vitro, it was unlikely that -due to high plasma protein binding of glyburide -a drug-drug interaction occurs in the clinical stage. Importantly however, the plasma protein binding of the wellknown OATP1B1 inhibitor cyclosporine A is high as well, with a predicted unbound portal vein concentration of cyclosporine A of ~0.5 µM (C max 1900 ng/ml at 400 mg dose with 98.6% plasma protein binding (Akhlaghi et al., 1997; Falck et al., 2008) . Whereas this value is also below the determined IC 50 value for inhibition of rosuvastain uptake into HEK-OATP1B1 cells (1.64 µM), co-administration of rosuvastatin with cyclosporine A in the clinic resulted in 5-to 10-fold higher systemic exposure to rosuvastatin, which could mainly be explained by inhibition of OATP1B1-mediated hepatic uptake of rosuvastatin (Asberg, 2003; Neuvonen et al., 2006; Simonson et al., 2004) . This indicates that a straightforward The frequency of the low-activity OATP1B1*15 differs between various geographical populations, ranging from only 2% and 9% in Sub-Saharan African and South/Central Asian population, respectively, to 15-24% in populations from North Africa, Europe, Middle East and America (Pasanen et al., 2008) . This rather high frequency of the OATP1B1*15 haplotype in selected populations demonstrates the importance of studying its effect on the disposition of drugs. Importantly, the effect of the *15 variation on drug-drug interaction at the level of OATP1B1 has never been systematically studied in vitro before. We found similar IC 50 values for inhibition of E 2 17β-G uptake into HEK-OATP1B1 and HEK-OATP1B1*15 cells for the different studied oral antidiabetics and the known inhibitors cyclosporine A, rifampicin and pravastatin. This indicates that the intrinsic affinity of OATP1B1 for these inhibitors is not affected by the amino acid changes in the *15 variant.
Further studies are needed to explore whether this is a general finding, or whether it is dependent on the substrate/inhibitor combination.
It has previously been reported that the lipophilicity of compounds can determine their inhibition capacity, as was reported for the metabolic enzyme CYP3A4 (Lewis et al., 2006; Regev-Shoshani et al., 2004) . We therefore explored whether this is also the case for inhibition of the transport protein OATP1B1, and indeed found that within the class of sulfonylureas an increased lipophilicity of the antidiabetic drugs was associated with an increased potency to inhibit OATP1B1-mediated transport of rosuvastatin.
This article has not been copyedited and formatted. The final version may differ from this version. In summary, we generated and fully characterized HEK-OATP1B1 and HEK-OATP1B1*15 cells and provide evidence for potentially important drug-drug interactions between rosuvastatin and selected sulfonylureas and thiazolidinediones. It remains to be established, however, whether the studied oral antidiabetics affect the clinical pharmacokinetic profile of rosuvastatin in patients. The in vitro studies as described can be considered as an important step in an intelligent pre-clinical test strategy to detect potential drug-drug interactions which need to be confirmed in subsequent (preclinical and/or clinical) studies to provide a decisive answer.
This article has not been copyedited and formatted. The final version may differ from this version. Compound lipophilicity (xlogP) LogIC50 (mM)
